Synapstim

Synapstim has developed the InRelief, a highly innovative product for a convenient, homecare treatment of overactive bladder (OAB), which is the cause for urge incontinence (UI). To date, OAB and UI are treated with pharmaceuticals, invasive clinic-based treatments or with implanted devices. For many OAB patients, these treatment options are ineffective, impractical, or associated with intolerable side effects. InRelief provides a technological breakthrough using neuromodulation which presents a treatment option for many millions of OAB and UI patients that up to now have gone untreated. People who suffer from OAB and UI will be able to treat themselves at home with the InRelief whenever they need and for whatever length of time required. OAB affects the daily lives of 71 million in Europe and 48 million in the US. More than 55% of OAB patients — that is, over 39 million sufferers in Europe alone — are untreated and seek a convenient (no need to go to the clinic), reasonably priced treatment without side effects. Synapstim is a start-up managed by experienced professionals in development and commercialisation of a unique technology in the area of neuromodulation and bioelectronic medicine. Its highly skilled team of scientists and engineers have more than 40 years of accumulated experience in neuromodulation. Synapstim’s flagship product is the InRelief. The company has performed successful clinical study that proved the initial safety and efficacy of InRelief prototype.